Court lifts ban on Keytruda in Germany

By Alice Dixon • November 21, 2026
Court lifts ban on Keytruda in Germany - keytruda germany
MSD markets pembrolizumab as Keytruda, one of the world’s best-selling cancer drugs, generating approximately €25.8 billion in sales for the US pharmaceutical company in 2024.

The Higher Regional Court Munich has lifted a preliminary injunction that previously blocked the launch of MSD’s subcutaneous version of cancer drug Keytruda in Germany. This decision marks a significant setback for US biotech Halozyme, which had secured the injunction from the Regional Court Munich in late 2025.

The dispute between Halozyme and Merck Sharp & Dohme centers on Halozyme’s European patent EP 2 797 622, which protects a polypeptide variant underlying the subcutaneous formulation of pembrolizumab. MSD markets pembrolizumab as Keytruda, one of the world’s best-selling cancer drugs, generating approximately €25.8 billion in sales for the US pharmaceutical company in 2024.

San Diego-based company Halozyme Therapeutics develops oncological therapies targeting the tumour’s microenvironment. Halozyme alleged infringement of its MDAS patent EP 622 by Keytruda SC, a subcutaneous formulation of the drug injected under the skin rather than administered by infusion.

The Munich Regional Court had granted the preliminary injunction in December 2025, prohibiting MSD from launching Keytruda SC in Germany. However, the Higher Regional Court Munich, under presiding judge Lars Meinhardt, overturned the first-instance decision and dismissed the preliminary injunction application.

Following the ruling, Halozyme announced that it is initiating main proceedings. Mark Snyder, Chief Legal Officer of Halozyme, stated: “We disagree with the decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief, which is not precluded by today’s decision”.

The German decision is part of a broader multi-jurisdictional dispute over Keytruda SC. MSD has filed nullity actions against EP 622 in Germany, the Netherlands, France, and the UK. Halozyme has pursued infringement claims in several of these jurisdictions, including a recent ruling by the District Court of The Hague upholding Halozyme’s European patent and issuing a cross-border injunction covering eight countries.

Parallel litigation is ongoing in the UK, where the High Court recently rejected MSD’s application for expanded disclosure of Halozyme’s experimental documents. In the US, Halozyme is pursuing litigation against MSD before the federal district court in New Jersey, alleging that Qlex, the subcutaneous formulation marketed there, infringes 15 patents relating to its MDAS technology.

Halozyme relied on a team from Quinn Emanuel Urquhart & Sullivan, led by Munich-based partner Marcus Grosch, in the German proceedings. MSD instructed its long-standing advisors from Hogan Lovells Cadwalader, with Düsseldorf-based partners Miriam Gundt and Andreas von Falck leading the German proceedings, working with patent attorney Felipe Zilly.

Leave a Reply

Your email address will not be published. Required fields are marked *